OXGENE’s proprietary cell and gene therapy manufacturing solutions help pioneering companies achieve high-titre, scalable and cost-effective viral vector production.
Streamlined ordering and manufacturing processes accelerate turnaround times and expedited local and international delivery for both standard and custom plasmids at all grades. Planned local stocks of standard plasmids will further reduce delivery times.
OXGENE’s plasmids are validated and optimized for use on WuXi Advanced Therapies’ (WuXi ATU) AAV GMP manufacturing platform, offering a seamless transition with reduced technology transfer times to high quality, high yield GMP grade AAV production for clinical or commercial use.
Download the resource to continue reading.